Stockreport

InflaRx Doses First Patient in Multicenter Randomized Clinical Trial in Severe Progressed COVID-19 Pneumonia in Europe upon Receipt of Initial Positive Human Data with InflaRx’s anti-C5a T...

InflaRx N.V.  (IFRX) 
Last inflarx n.v. earnings: 8/14 04:05 pm Check Earnings Report
PDF InflaRx has dosed the first patient in an adaptive randomized controlled clinical study with IFX-1 in patients with severe COVID-19 pneumonia in the NetherlandsInflaRx r [Read more]